SG11202111311WA - Pharmaceutical parenteral composition of dual glp1/2 agonist - Google Patents
Pharmaceutical parenteral composition of dual glp1/2 agonistInfo
- Publication number
- SG11202111311WA SG11202111311WA SG11202111311WA SG11202111311WA SG11202111311WA SG 11202111311W A SG11202111311W A SG 11202111311WA SG 11202111311W A SG11202111311W A SG 11202111311WA SG 11202111311W A SG11202111311W A SG 11202111311WA SG 11202111311W A SG11202111311W A SG 11202111311WA
- Authority
- SG
- Singapore
- Prior art keywords
- agonist
- parenteral composition
- pharmaceutical parenteral
- dual glp1
- glp1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19180233 | 2019-06-14 | ||
| PCT/EP2020/066376 WO2020249778A1 (en) | 2019-06-14 | 2020-06-12 | Pharmaceutical parenteral composition of dual glp1/2 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111311WA true SG11202111311WA (en) | 2021-12-30 |
Family
ID=66867001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111312UA SG11202111312UA (en) | 2019-06-14 | 2020-06-12 | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| SG11202111311WA SG11202111311WA (en) | 2019-06-14 | 2020-06-12 | Pharmaceutical parenteral composition of dual glp1/2 agonist |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111312UA SG11202111312UA (en) | 2019-06-14 | 2020-06-12 | Pharmaceutical parenteral composition of dual glp1/2 agonist |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220202704A1 (en) |
| EP (2) | EP3982919A1 (en) |
| JP (2) | JP2022535556A (en) |
| KR (2) | KR20220020821A (en) |
| CN (2) | CN113966225A (en) |
| AU (2) | AU2020290014B2 (en) |
| BR (1) | BR112021024651A2 (en) |
| CA (2) | CA3138715A1 (en) |
| CL (2) | CL2021003273A1 (en) |
| IL (2) | IL286991A (en) |
| MX (2) | MX2021015154A (en) |
| SG (2) | SG11202111312UA (en) |
| WO (2) | WO2020249778A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4294424A1 (en) | 2021-02-18 | 2023-12-27 | Zealand Pharma A/S | Composition for treating short bowel syndrome |
| TW202315882A (en) | 2021-09-03 | 2023-04-16 | 丹麥商西蘭製藥公司 | Dosage regime |
| CN116655772A (en) * | 2022-02-18 | 2023-08-29 | 成都奥达生物科技有限公司 | Long-acting GLP-1/GLP-2 dual agonist compound |
| WO2024061919A1 (en) * | 2022-09-19 | 2024-03-28 | Zealand Pharma A/S | Combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0929567T3 (en) | 1996-09-09 | 2005-06-27 | Zealand Pharma As | Enhanced solid phase peptide synthesis and means for using such a synthesis |
| WO2013164484A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| CN105849122B (en) * | 2013-11-06 | 2021-04-30 | 西兰制药公司 | GIP-GLP-1 dual agonist compounds and methods |
| EP3212217A1 (en) | 2014-10-31 | 2017-09-06 | Gubra ApS | Compositions and peptides having dual glp-1r and glp-2r agonist activity |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| KR102502040B1 (en) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | Acylated GLP-1/GLP-2 dual agonists |
-
2020
- 2020-06-12 MX MX2021015154A patent/MX2021015154A/en unknown
- 2020-06-12 KR KR1020217040797A patent/KR20220020821A/en unknown
- 2020-06-12 SG SG11202111312UA patent/SG11202111312UA/en unknown
- 2020-06-12 US US17/617,675 patent/US20220202704A1/en active Pending
- 2020-06-12 JP JP2021572035A patent/JP2022535556A/en active Pending
- 2020-06-12 CA CA3138715A patent/CA3138715A1/en active Pending
- 2020-06-12 AU AU2020290014A patent/AU2020290014B2/en active Active
- 2020-06-12 JP JP2021572029A patent/JP2022535555A/en active Pending
- 2020-06-12 WO PCT/EP2020/066376 patent/WO2020249778A1/en unknown
- 2020-06-12 CN CN202080043001.8A patent/CN113966225A/en active Pending
- 2020-06-12 CA CA3138716A patent/CA3138716A1/en active Pending
- 2020-06-12 AU AU2020293576A patent/AU2020293576A1/en active Pending
- 2020-06-12 BR BR112021024651A patent/BR112021024651A2/en unknown
- 2020-06-12 EP EP20731149.9A patent/EP3982919A1/en active Pending
- 2020-06-12 SG SG11202111311WA patent/SG11202111311WA/en unknown
- 2020-06-12 WO PCT/EP2020/066381 patent/WO2020249782A1/en active Application Filing
- 2020-06-12 US US17/617,670 patent/US20230212227A1/en active Pending
- 2020-06-12 EP EP20731150.7A patent/EP3982920A1/en active Pending
- 2020-06-12 MX MX2021015153A patent/MX2021015153A/en unknown
- 2020-06-12 CN CN202080043314.3A patent/CN113966226A/en active Pending
- 2020-06-12 KR KR1020217040768A patent/KR20220020819A/en unknown
-
2021
- 2021-10-05 IL IL286991A patent/IL286991A/en unknown
- 2021-10-05 IL IL286990A patent/IL286990A/en unknown
- 2021-12-09 CL CL2021003273A patent/CL2021003273A1/en unknown
- 2021-12-09 CL CL2021003272A patent/CL2021003272A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138716A1 (en) | 2020-12-17 |
| CN113966225A (en) | 2022-01-21 |
| EP3982920A1 (en) | 2022-04-20 |
| JP2022535556A (en) | 2022-08-09 |
| CL2021003273A1 (en) | 2022-07-22 |
| US20230212227A1 (en) | 2023-07-06 |
| CL2021003272A1 (en) | 2022-07-22 |
| BR112021024651A2 (en) | 2022-01-04 |
| AU2020290014A1 (en) | 2021-11-04 |
| JP2022535555A (en) | 2022-08-09 |
| CN113966226A (en) | 2022-01-21 |
| SG11202111312UA (en) | 2021-12-30 |
| IL286991A (en) | 2021-12-01 |
| CA3138715A1 (en) | 2020-12-17 |
| MX2021015153A (en) | 2022-01-18 |
| KR20220020821A (en) | 2022-02-21 |
| AU2020290014B2 (en) | 2022-10-27 |
| IL286990A (en) | 2021-12-01 |
| US20220202704A1 (en) | 2022-06-30 |
| MX2021015154A (en) | 2022-01-18 |
| EP3982919A1 (en) | 2022-04-20 |
| AU2020293576A1 (en) | 2021-11-04 |
| WO2020249782A1 (en) | 2020-12-17 |
| KR20220020819A (en) | 2022-02-21 |
| WO2020249778A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286990A (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
| IL288479A (en) | Glucagon-like peptide 1 receptor agonists | |
| IL279442A (en) | Pharmaceutical compositions comprising meloxicam | |
| IL279504A (en) | Gip/glp1 agonist compositions | |
| GB2599045B (en) | Prevention of dripping of material for material injection | |
| IL276888A (en) | Pharmaceutical composition comprising timolol | |
| SG11202111488YA (en) | Solid pharmaceutical composition comprising tlr7 agonist | |
| EP3305316A4 (en) | Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist | |
| EP3582759A4 (en) | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide | |
| IL291502A (en) | Agonist of tacr2 | |
| IL288536A (en) | Il2 agonists | |
| IL276783A (en) | Novel compound and pharmaceutical composition compirisng same | |
| IL285389A (en) | Pharmaceutical compositions comprising meloxicam | |
| ZA202006157B (en) | Pharmaceutical composition of kor receptor agonist | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| FI3908321T3 (en) | Pharmaceutical composition | |
| GB201913701D0 (en) | Composition of matter | |
| IL285728A (en) | Pharmaceutical composition | |
| GB201912686D0 (en) | Pharmaceutical composition | |
| GB201908003D0 (en) | Pharmaceutical composition | |
| IL279707A (en) | Pharmaceutical composition comprising polypeptide | |
| EP3972578C0 (en) | Ternary pharmaceutical composition of s1pr modulators | |
| GB201904767D0 (en) | New pharmaceutical compositions | |
| GB201904783D0 (en) | New pharmaceutical compositions | |
| GB201904785D0 (en) | New pharmaceutical compositions |